Prevention of placental malaria through administration of antimalarial medications to pregnant women in disease-endemic areas decreases the risk of delivery of low birth weight (LBW) infants. In areas of high Plasmodium falciparum transmission, two intermittent presumptive treatment doses of sulfadoxine-pyrimethamine (SP) during the second and third trimesters of pregnancy are effective in decreasing the prevalence of placental malaria in human immunodeficiency virus (HIV)-negative women, while HIV-positive women may require a monthly SP regimen to reduce their prevalence of placental parasitemia. A decision-analysis model was used to compare the costeffectiveness of three different presumptive SP treatment regimens with febrile case management with SP in terms of incremental cost per case LBW prevented. Factors considered included HIV seroprevalence, placental malaria prevalence, LBW incidence, the cost of SP, medical care for LBW infants, and HIV testing. For a hypothetical cohort of 10,000 pregnant women, the monthly SP regimen would always be the most effective strategy for reducing LBW associated with malaria. The two-dose SP and monthly SP regimens would prevent 172 and 229 cases of LBW, respectively, compared with the case management approach. At HIV seroprevalence rates greater than 10%, the monthly SP regimen is the least expensive strategy. At HIV seroprevalence rates less than 10%, the two-dose SP regimen would be the less expensive option. When only antenatal clinic costs are considered, the two-dose and monthly SP strategies cost US$11 and $14, respectively, well within the range considered cost effective. Presumptive treatment regimens to prevent LBW associated with malaria and the subsequent increased risk of mortality during the first year of life are effective and cost effective strategies in areas with both elevated HIV prevalence and malaria transmission rates.
INTRODUCTION
In malarious areas, pregnant women are more likely than nonpregnant women to be malaria infected and to have higher density parasitemias. 1, 2 In areas of high Plasmodium falciparum transmission, although pregnant women infected with malaria may be asymptomatic, parasites can sequester in the placenta and cause alterations in its structure. [3] [4] [5] Placental malaria is associated with low birth weight (LBW), [6] [7] [8] the single greatest risk factor for neonatal mortality and a major contributor to infant mortality, 9 presumably because it interferes with nutrient transfer to the fetus. 4, 5 In high malaria transmission areas, where women have acquired substantial malarial immunity, primigravidae and secundigravidae are most at risk for malaria infection 8, 10 and malaria-associated LBW. 1, 2, 10 The World Health Organization (WHO) had previously recommended that pregnant women living in malarious areas receive full antimalarial treatment at the first antenatal clinic visit, followed by regular chemoprophylaxis during pregnancy. 11 However, the spread of chloroquine resistance has made the choice of an efficacious and safe prevention regimen difficult. More recently, the Twentieth WHO Expert Committee on Malaria recommended intermittent treatment for prevention of adverse effects of malaria infection during pregnancy for women in highly endemic areas. 12 Two presumptive treatment doses of sulfadoxine-pyrimethamine (SP), administered once in the second and once in the third trimester of pregnancy, have been shown to be efficacious at decreasing placental malaria in sub-Saharan Africa. 13, 14 In addition, in Malawi, women who received two or more doses of SP were less likely to deliver LBW infants compared with women who received only one dose of SP. 15 A recent study in Kenya 14 has examined the efficacy of SP in decreasing placental parasitemia and LBW in human immunodeficiency virus (HIV)-positive women compared with HIV-negative ones. This investigation showed that while two intermittent SP treatment doses are sufficient to decrease placental parasitemia rates in HIV-negative women, HIV-positive women required a monthly treatment regimen (achieving at least three doses of SP) to attain similar outcomes. In HIV-negative women, two doses of SP decreased the prevalence of placental parasitemia from 23% to 7%. However, in HIVpositive women, two doses only resulted in a decrease in prevalence from 45% to 26% while a monthly SP regimen achieved a 7% placental infection rate.
Although findings of reduced SP efficacy in HIV-positive compared with HIV-negative women should be confirmed in other studies, as we begin to consider the various antenatal program options for preventing malaria-associated LBW, one possibility would be to test pregnant women for HIV antibodies and treat with either a two-dose SP or a monthly SP regimen based on the women's HIV test results. However, many antenatal clinic settings in the developing world do not routinely offer HIV testing to pregnant women. Therefore, another option would be to treat the pregnant women based on the population HIV seroprevalence. Using this approach, an area with a ''high'' HIV seroprevalence among women of childbearing age would use a monthly SP dosing program, while an area with a ''low'' HIV seroprevalence would use a two-dose SP program. If this option were chosen, one must determine the HIV seroprevalence rate above which health policy makers would rationally choose a monthly SP treatment scheme and, below which, a two-dose SP scheme would be chosen.
We conducted a cost-effectiveness analysis to determine 1) the most cost-effective program option, in terms of cost per case LBW prevented; 2) the HIV seroprevalence rate, above which it is most cost-effective to use a monthly SP regimen and, below which, a two-dose SP regimen; and 3) other factors, such as the prevalence of placental parasitemia, that influence the cost-effectiveness of the various program options. METHODS We constructed a decision model to examine the cost effectiveness of three different regimens of presumptive intermittent treatment with SP and a program employing a febrile case management (CM) approach for the prevention of LBW due to placental malaria in pregnant primigravidae and secundigravidae. The regimens examined included 1) two-dose SP, with one dose given at the first antenatal clinic (ANC) visit, usually occurring in the second trimester, and a second dose given early in the third trimester; (2) monthly SP, with the first dose given at the first ANC visit, followed by monthly dosing through the ninth month of gestation; 3) HIV testing followed by SP treatment according to HIV serostatus (two doses for HIV-negative women and monthly doses for HIV-positive women); and 4) febrile CM, in which women were treated for malaria when they have fever accompanied by parasitemia during pregnancy. Each SP treatment dose consisted of an oral dose of 1,500 mg of sulfadoxine and 75 mg of pyrimethamine. The febrile CM approach was chosen as the standard for comparison as it is still commonly being used in many countries in sub-Saharan Africa. We also included a comparison arm of no malaria care, in which women would not receive treatment for malaria, since this enables one to examine the utility of only using a CM approach. (Although programs would not intentionally withhold therapy, this could occur, for example, if drugs were not available or if women were given a prescription that they were unable to fill because they lacked funds.)
The decision tree ( Figure 1 ) was constructed to compare the four treatment options in a hypothetical cohort of 10,000 pregnant women attending an ANC whose individual HIV serostatus was unknown. The model assumed that each pregnancy resulted in a single live birth. The model incorporated parameter estimates for HIV prevalence among pregnant women, the proportion of pregnant women attending an ANC, the proportion of pregnant women consenting to HIV testing, positive and negative predictive values for enzymelinked immunosorbent assay (ELISA) testing, the prevalence of placental malaria, and the incidence of LBW in infants born to mothers with and without placental parasitemia (Table 1).
The model was analyzed from the health care system cost perspective, which included ANC program costs for malaria care (costs for SP doses and HIV testing) as well as medical care costs for LBW infants. All costs are reported in 1997 U.S. dollars. Costs from previous years were adjusted using a 5% annual inflation rate. 16 Analysis was conducted using DATA by TreeAge software (version 3.5.1; TreeAge, Williamstown, MA). DATA is a computer-based software package for constructing probabilistic decision models that estimate expected values for specified outcomes. The model calculated the expected number of LBW infants associated with placental parasitemia, the disabilityadjusted life years (DALYs) lost due to LBW-associated neonatal and postneonatal mortality, and the health care costs of each treatment option. Treatment options were ranked by order of effectiveness to calculate the expected number of LBW infants prevented by, the DALYs saved by, and the additional cost of each strategy when compared to the previous most effective one and no malaria care. Two sets of ratios are reported: the average and incremental net cost per LBW birth prevented and the average and incremental ANC program cost per DALY gained. The net cost is defined as the ANC program cost minus the health care costs of LBW prevented.
Parameter estimates. Because the primary source of our data on the efficacy of SP in reducing placental malaria in HIV-positive compared with HIV-negative women was western Kenya, we constructed the baseline scenario represen-tative of that region. Parameter estimates were derived from a review of existing literature and unpublished studies ( Table  1) . We used an HIV seroprevalence rate of 27% in the cohort of pregnant women attending an ANC and estimated that 80% of these women would participate in HIV testing if offered (Nahlen B, unpublished data).
The World Health Organization recommends HIV testing using two ELISA tests for countries with HIV seroprevalence rates greater than 10%. 17 The model includes the positive and negative predictive values for the double testing procedure. 18 The baseline estimates of the prevalence of placental parasitemia in HIV-positive and HIV-negative women were parity adjusted and stratified by the number of SP doses received. 14 The conditional probability range was calculated using the confidence interval that encompassed one standard deviation on either side of the mean. No HIV-positive women who received three or more doses of SP had placental malaria; due to sample size limitations, it was not possible to make a non-zero estimation of the rate to calculate a confidence interval. For this stratum, we therefore use a sum- mary rate combining HIV-positive and HIV-negative women.
The probability that a pregnant woman would receive one, two, or three SP doses is based on the number of ANC visits made during pregnancy in studies in western Kenya 14 (Parise M, unpublished data) . Data from the Kisumu study 14 indicate that although women were asked to come monthly for follow-up visits, they often do not strictly adhere to such a schedule. In sub-Saharan Africa, most women make their first ANC visit in the second trimester; 19 thus, opportunities to receive more than three doses of SP are limited.
Estimates for the incidence of LBW, in women with and without placental parasitemia, were derived from studies in western Kenya (Parise M, unpublished data). These estimates are consistent with the range observed in several other studies from sub-Saharan Africa. 1, [20] [21] [22] [23] [24] The two causes of LBW (Ͻ 2,500 grams) are prematurity and intrauterine growth retardation (IUGR). Infant mortality rates for premature (Ͻ 37 weeks gestation) LBW infants are higher than for term infants (Ն 37 weeks) with LBW due to IUGR. 20, 24, 25 In areas of high P. falciparum transmission, placental malaria infection is associated with both IUGR 1,20,21 and prematurity. 20 This analysis limited its focus to LBW and its associated mortality rates due to IUGR. Probability estimates for neonatal and postneonatal mortality rates for normal and LBW infants were obtained from a cohort study in Malawi that assessed the impact of malaria on women and infants, 26 and is well within the range observed in other sub-Saharan African studies. 20, [27] [28] [29] [30] [31] The DALYs lost due to LBW for each of the treatment options were based on the neonatal and postneonatal mortality rates for LBW infants and a disability-adjusted life expectancy (DALE) at birth of 39.4 years for Kenya discounted at 3%. 32 We assumed that infants who did not survive the postneonatal period lost their full DALE. Thus, each LBW-associated death resulted in a loss of 23.62 discounted DALYs. We conducted sensitivity analysis over the range in DALE for countries in sub-Saharan Africa. 32 Costs. The model includes ANC costs for HIV counseling and testing and doses of SP, and medical care costs for LBW infants in excess of the cost for a normal delivery ( Table 2) . Because our cost effectiveness analysis took the health care system perspective, costs for loss of productivity were not considered. Testing for antibody to HIV included the cost of two ELISAs and pre-and post-test counseling. 33, 34 The cost of SP included the drug cost and the costs of shipping, handling, and insurance. 11, 35 The cost of an ANC visit was not included because SP would be administered during routine ANC visits the women were already making. Women in the monthly SP arm of the model who returned after receiving the second dose were assumed to receive a total of 3.4 doses of SP. This is based on data from the Kisumu clinical trial where women who made more than two visits returned, on average, 3.4 times.
Limited data were available on the medical care costs of LBW infants. 31 We have estimated that a LBW infant requires, on average, 11.65 additional days of in-patient pediatric care following delivery day 27 at a cost of $4.00 per day (Sliney I, unpublished data). The costs do not include those for the delivery and hospitalization of the mother. Costs after hospital discharge, including those borne by the family, such as for home care of an LBW infant or out-ofpocket expenses for medications, were also not included because of lack of data. In the baseline model it was assumed that all LBW infants were hospitalized after delivery.
Sensitivity analysis. We performed univariate analyses on all parameter estimates to test their influence on the results. We conducted multivariate analyses to adapt the model to represent the range of conditions found in sub-Saharan Africa. Estimates changed in multivariate analyses included the HIV seroprevalence in pregnant women, 14, 36, 37 the percentage of pregnant women attending ANC 28, 38 and receiving malaria treatment, the incidence of LBW, the rates of placental parasitemia, the cost of HIV testing and counseling, the cost of SP, the probability that a LBW infant would be hospitalized following delivery, the costs of treating LBW infants, 27, 31, 39 and country-specific DALEs. The ranges and sources for the parameter estimates we used are shown in Tables 1 and 2 .
RESULTS
The results are shown in Tables 3 and 4 . In a cohort of 10,000 pregnant women with a 27 percent HIV seroprevalence, the monthly dose SP regimen would be the most effective strategy for preventing LBW associated with placental malaria in the mothers. When ranked in order of effectiveness, the case management strategy is the least effective strategy followed by the two-dose SP regimen, the HIV testing strategy, and the monthly SP strategy. The addition of the monthly SP regimen to ANC for women receiving no treatment for malaria would prevent LBW in 256 infants and save 311 DALYs. In ANC programs already offering treatment for malaria, switching from a case management strategy to the monthly SP regimen would prevent LBW in 229 infants and save 171 DALYs.
The monthly SP strategy would be the least expensive strategy when costs associated with LBW are included in the analysis. When considering only additional ANC program costs for malaria care, the three nondominated strategies would range from $10 to $14 per DALY gained when compared with no malaria care during pregnancy. (The HIV testing strategy is dominated by the monthly SP strategy because it is a more expensive and less effective strategy.) The cost of employing the monthly SP regimen when compared with the two-dose SP regimen would be $23 dollars per DALY gained for each of the additional 71 DALYs by implementing the monthly SP regimen rather than the two-dose regimen. Sensitivity analysis. Regardless of changes in the variables in the analysis, the effectiveness ranking of the four strategies remain unchanged. The monthly SP strategy would always be the most effective at preventing LBW associated with malaria. The probability that placental parasitemia would result in LBW and the probability that pregnant women would have access to and accept SP are the factors which most influence the effectiveness of all of the strategies.
The total costs were most affected by the probability that a LBW infant would be hospitalized after delivery, the costs associated with a LBW infant, the cost of SP, and the probability that placental parasitemia would result in LBW. The probability that a LBW infant would be hospitalized after delivery and the costs associated with LBW had the greatest impact on cost effectiveness. Although the monthly SP strategy was always the most cost-effective, the two-dose strategy becomes the least expensive strategy when the probability that a LBW infant would be hospitalized ranges from 0.4 to 0.7. Below a probability of 0.4, case management would be the least expensive, but not the most effective, approach. When the cost of a dose of SP increased to $0.22, the total cost for the monthly SP strategy and two-dose SP strategy were equivalent. When the cost of a dose of SP was increased to $0.40, the total cost of the monthly SP strategy was the same as for the case management strategy. However, the monthly SP strategy remains more cost effective because it is always more effective in reducing LBW.
Because the prevalence of HIV infection in pregnant women varies across sub-Saharan Africa, we performed breakeven analysis on costs and effectiveness over a range in HIV seroprevalence. Regardless of HIV seroprevalence, the monthly SP regimen would always be the most effective strategy for preventing LBW associated with placental malaria. However, when the HIV seroprevalence falls below 10%, the monthly SP strategy ceases to be less costly than the two-dose SP strategy. Even at low HIV seroprevalence rates, the monthly dose SP strategy is less than $25 per DALY gained, a range still considered cost-effective. In areas with lower malaria transmission rates (as indicated by the probability of placental parasitemia) the monthly SP strategy becomes more costly than the two-dose SP strategy but its cost-effectiveness ratio always remains within a range considered cost effective. Again, this is because the monthly SP strategy is the most effective strategy for reducing LBW associated with malaria regardless of the malaria transmission rate.
In all settings, both effectiveness and cost effectiveness can be improved by efforts to increase access to and acceptance of any of the strategies to prevent LBW associated with placental malaria. Figure 2 demonstrates the impact of increasing the probability that a pregnant woman receives at least the first dose of SP on her risk of delivering a LBW infant. DISCUSSION We examined malaria prevention strategies in pregnant women because of evidence that presumptive intermittent treatment with SP is efficacious in decreasing the prevalence of placental malaria, and thereby reduces the risk of delivery of LBW infants. [13] [14] [15] However, one must also consider the ability to deliver various prevention regimens. The two-dose SP regimen can conveniently be combined with the administration of the two doses of tetanus toxoid that are provided to primigravidae in many countries. Alternatively, monthly doses can be administered (e.g., along with hematinics) at routine visits that are scheduled for women as part of many national antenatal care programs. In many countries in sub-Saharan Africa, women are currently making, on average, three to four antenatal clinic visits during pregnancy. 19 Thus, the use of a monthly SP regimen ensures routine delivery of three or four treatment doses and is simpler for health care workers to employ than is the use of a set three-dose regimen, which would require clinicians to administer and document doses given at specific gestational periods. Although the HIV testing regimen is more complicated, since it requires adequate laboratory facilities and trained counseling staff, we thought it was important to consider this option because of noted differences in the efficacy of SP in reducing placental malaria in HIV-positive women compared with HIV-negative women. 14, 15 The two-dose SP, monthly SP, and HIV-testing regimens all decreased placental parasitemia rates in primigravidae and secundigravidae and were estimated to avert more cases of LBW than the febrile case management approach. Although ANC costs for SP were higher for the two-dose and monthly-dose presumptive treatment regimens, the estimated incidence of LBW cases was lower and, therefore, medical care costs were lower, producing lower overall health care costs. When compared with the two-dose SP regimen, the monthly-SP regimen averted more cases of LBW at a minimal additional SP program cost and resulted in a greater savings in total health care costs compared with the twodose SP regimen. The HIV testing and counseling strategy was much more expensive than any of the other regimens. Thus, if the goal is to prevent malaria-associated LBW and treatment to prevent perinatal HIV transmission is not available, it is more cost-effective to base SP dose regimen decisions on the population seroprevalence rate rather than on individual HIV test results. Though we have focused on LBW, intermittent presumptive therapy with SP has also been shown to decrease severe maternal anemia, which would reduce both maternal mortality and LBW and thus tend to make the interventions even more cost effective. 40 Basing doses received in the case management arm on clinical, rather than parasitologic diagnosis, could affect both costs and efficacy of the case management arm. As doses of SP received increase, the case management arm may appear progressively more like the two-dose SP and monthly SP arms.
When considering only the ANC costs for malaria treatment, the cost effectiveness of two-dose and monthly SP regimens ranged from $11 to $14 per DALY gained. Compared with cost-effectiveness ratios for other malaria interventions, presumptive treatment with SP during pregnancy is one of the most cost-effective strategies for preventing morbidity and mortality associated with malaria. 41 When the costs of hospitalization for LBW are also included, the monthly SP and two-dose SP regimens would be cost saving when the cost of a dose of SP is less than $0.40. Thus, such presumptive intermittent treatment programs will be cost effective and produce cost savings in many settings, since most countries should be able to purchase SP at costs in the $0.10-0.15 range. 11, 35 Perinatal HIV transmission is a serious problem in sub-Saharan Africa, with transmission rates between 16% and 24% in many settings. 42 If the implementation of perinatal antiretroviral programs becomes feasible in developing countries, antenatal program goals may expand to include testing for maternal HIV status to target the vertical transmission prevention program. In this case, the decision model may change and the HIV testing arm could become the most cost-effective option because its costs would be shared by multiple effective disease reduction programs. Although antiretroviral drugs for perinatal HIV prevention are not currently utilized in many sub-Saharan African countries, the demonstrated benefits of short-course interventions may contribute to evolution in antenatal care so that HIV prevention may be introduced in the future. 36, [43] [44] [45] Our study had several limitations. No single study has yet demonstrated a statistically significant decrease in the incidence of LBW with intermittent presumptive treatment using SP, due in part to the multifactorial etiology of LBW and the large sample sizes needed to demonstrate effects on LBW. However, clear trends are evident and thus we believe that the assumption made in our decision model, i.e., that intermittent presumptive treatment with SP can reduce LBW, is valid. Two controlled trails have shown a trend towards a decreased incidence in LBW infants born to mothers on intermittent presumptive treatment with SP compared with CM 14 or compared with chloroquine-containing regimens. 13 A statistically significant increase in mean birth weight has been demonstrated, 14 as well as a dose effect, where a significant decrease in the incidence of LBW infants was seen in women who have received one compared with two doses of SP. 15 In addition, there is clear evidence that SP reduces placental malaria, 14 that placental malaria is associated with an increased risk for delivery of LBW infants, and that administration of an efficacious antimalarial drug during gestation decreases the incidence of LBW infants. 20 Because of a scarcity of published data on the cost of medical care of a LBW infant in developing countries, an estimate was obtained by multiplying the average length of hospitalization for an infant with IUGR by the cost of care in a general pediatric unit. Costs may have been underestimated because general pediatric ward costs (the only data available) were used and because the model did not take into account the out-of-pocket costs to family, costs to society, lost productivity, and medical care costs associated with future medical conditions caused by LBW, and the higher medical costs of very LBW (Ͻ 1,500 grams) infants compared with all LBW infants. However, the model may also have overestimated these medical care costs because many women do not deliver in a hospital, 29 and thus, not all infants with LBW will receive this medical care. We attempted to adjust for this latter factor in the sensitivity analysis; the conclusions in our cost-effectiveness analysis were robust when varied from the minimum to the maximum estimates in the sensitivity analysis. Because there are no data on a direct correlation between parasitologic resistance or clinical failure rates on prevalence rates of placental parasitemia, we did not include drug resistance per se in the model. However, drug efficacy is certainly one factor in the variation in rates of placental parasitemia that may be seen at varying doses of SP and thus, were indirectly reflected in the range of values used for placental parasitemia in the sensitivity analysis. That is, as antimalarial drug resistance increases, the rate of placental parasitemia will increase for a given number of SP doses.
Training costs for health care workers and costs for health education of the community, which would likely be required to begin implementation of a new program, were not included in our model as these costs would be similar for a two-dose or monthly SP regimen. Because an HIV testing approach is somewhat more complicated, training costs may be higher for that strategy. Although these costs would be primarily start-up and not continuing costs, a country that is planning to implement a new antenatal strategy, such as presumptive intermittent SP treatment, would have to consider them. Other administrative and institutional costs to implement an SP program were not included as we assumed the delivery of SP would be incorporated into existing antenatal services. The costs for administering the SP doses would be similar among the three regimens and, therefore would not influence the difference in cost-effectiveness between regimens.
We did not include the cost of adverse drug reactions (ADRs) in our model because we assumed that the difference in the rate of serious ADRs would not vary significantly among the three presumptive treatment arms. The severe cutaneous reactions seen with SP are related to duration of use 46 and thus, have been a problem with regular malaria prophylaxis rather than intermittent treatment. More lives will be saved because of the reduction of LBW-associated infant mortality than will be lost due to serious ADRs among women receiving medication. The risk of death due to ADRs is estimated at 1/10,000 47 compared to the excess risk of mortality due to LBW in a 10,000 LBW infant cohort, which is approximately 625/10,000. 20 Both pyrimethamine and sulfonamides are considered to be safe during pregnancy and do not cause harm to the fetus. 48 We did not note significant differences in the rates of ADRs due to SP among HIVpositive compared with HIV-negative women in our Kenya trial. 14 Another potential adverse effect of SP use is its effect on host flora and antibiotic resistance; more information is needed on the magnitude of this potential problem and its costs before it could be included in a model. There have also been concerns about whether prevention of malaria in the mother will render the newborn and young infant more susceptible to malaria infection, though limited evidence to date argues against this. 49 Finally, we limited our analysis to women in their first and second pregnancies because malaria-associated LBW is primarily a problem of primigravidae and secundigravidae in areas of high malaria transmission. In addition, most of the available published data on the efficacy of SP in reducing rates of placental malaria in HIV-positive compared with HIV-negative women focuses on primigravidae and secundigravidae. 14 However, recent findings of high placental malaria rates in HIV-positive multigravidae 50 raise the question of whether antimalarial interventions should be extended to women of all parities; this issue merits further investigation.
Our results demonstrate that administering two-dose or monthly dose presumptive SP treatment to primigravidae and secundigravidae in the second and third trimesters of gestation were cost savings strategies over a case management approach to reduce the incidence of malaria-associated LBW and that cost savings are realized even in areas of low malaria transmission. Policy makers and program managers should consider the drug efficacy and cost-effectiveness of SP regimens, the prevalence of HIV in pregnant women, and the malaria and LBW prevention opportunities when selecting and designing antenatal care packages in areas of chloroquine-resistant P. falciparum.
